

**Lactate Dehydrogenase as a  
Biomarker for Prediction of  
Refractory  
*Mycoplasma pneumoniae*  
Pneumonia in Children**

**BS NGUYỄN THỊ NGỌC DIỄM  
KHOA NỘI 3**

# Introduction

- **Mycoplasma pneumoniae (MP)**: one of the most prevalent pathogens causing CAP in children (40% CAP, 18% require hospitalization)
- **Mycoplasma pneumoniae pneumonia (MPP)** :
  - +usually self-limited
  - +sometimes various pulmonary and extra-pulmonary complications
  - +the host's immune response >> direct microbial damage
- **Refractory Mycoplasma pneumoniae pneumonia (RMPP)**:
  - +clinical and radiological deterioration /macrolide antibiotic therapy  $\geq 7$  days
  - +steroid administration is reported to be effective in this situation

→ to recognize RMPP early ?

# Does LDH predict RMPP?

1. Clinical implications of interleukin-18 levels in pediatric patients with MPP. Tomohiro Oishi et al 2011
2. Management of RMPP: Utility of measuring serum lactate dehydrogenase level. Norikazu Inamura et al 2014
3. Lactate Dehydrogenase as a Biomarker for Prediction of RMPP in Children Aizhen Lu MD PhD et al 2015
4. The Clinical Characteristics and Predictors of RMPP. Yuanyuan Zhang et al 2016



# Clinical implications of interleukin-18 levels in pediatric patients with *Mycoplasma pneumoniae* pneumonia

Tomohiro Oishi · Mitsuo Narita · Kou Matsui · Takahiro Shirai ·  
Mai Matsuo · Jun Negishi · Takayuki Kaneko · Shinya Tsukano ·  
Tetsuo Taguchi · Makoto Uchiyama

Received: 7 February 2011 / Accepted: 30 May 2011 / Published online: 17 June 2011

© Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2011

## METHODS

- admitted to the Niigata Prefectural Shibata Hospital
- from 8/ 2006 to 2/ 2008, n = 23

## RESULTS

- IL-18 levels :abnormally elevated, Relationship between IL-18 values and severity
- the correlation between **IL-18 and LDH**: statistically significant ( $r^2= 0.64$ )
- /other clinical parameters: WBC, NEU, CRP, -AST, -ALT: not significant
- the usefulness LDH levels : measures of the severity of pediatric MPP



Original article

## Management of refractory *Mycoplasma pneumoniae* pneumonia: Utility of measuring serum lactate dehydrogenase level

Norikazu Inamura<sup>a</sup>, Naoyuki Miyashita, MD, PhD<sup>b,\*</sup>, Shunji Hasegawa<sup>c</sup>, Atsushi Kato<sup>a</sup>,  
Yoko Fukuda<sup>a</sup>, Aki Saitoh<sup>a</sup>, Eisuke Kondo<sup>a</sup>, Hideto Teranishi<sup>a</sup>, Tokio Wakabayashi<sup>a</sup>,  
Hiroto Akaike<sup>a</sup>, Takaaki Tanaka<sup>a</sup>, Satoko Ogita<sup>a</sup>, Takashi Nakano<sup>a</sup>, Kihei Terada<sup>a</sup>,  
Kazunobu Ouchi<sup>a</sup>

© 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Disease

### METHODS

-4 /2010 to 11/ 2012

-admitted Kawasaki Medical School Hospital and  
Yamaguchi University Hospital

- 20 pediatric patients MP (+)
- 5 RMPP / 15 GMPP (control group)

# RESULTS


Laboratory findings of 20 pediatric patients with *M. pneumoniae* pneumonia.

Laboratory findings <sup>a</sup>	Refractory group		Control group	p-Value	
	At admission	At initiation of steroid use		At admission vs control	At initiation of steroid use vs control
WBC (/μL)	4610 (2840–7460)	5370 (2000–13500)	5700 (3720–12210)	0.0887	0.7600
CRP (mg/d/L)	1.2 (0.5–6.3)	1.3 (0.3–3.5)	1.4 (0.3–6.7)	0.9652	0.5412
TP (g/dL)	6.8 (5.9–7.4)	6.9 (5.4–7.6)	7.2 (6.4–8.0)	0.0887	0.3155
LDH (IU/L)	331 (280–680)	571 (299–3606)	292 (208–395)	0.1266	0.0129
ALT (IU/L)	12 (9–16)	25 (13–44)	11 (7–33)	0.9203	0.0143
AST (IU/L)	29 (23–55)	41 (25–159)	26 (16–55)	0.5157	0.0404
IL-2 (pg/mL)	0 (0–3.0)	0 (0–1.6)	2.6 (0–3.7)	0.2317	0.1263
IL-4 (pg/mL)	0 (0–3.9)	0 (0–6.5)	0 (0–3.5)	0.2479	0.4237
IL-6 (pg/mL)	16.2 (12.9–81.7)	12.9 (7.3–28.6)	23.1 (7.1–135.6)	0.6169	0.0887
IFN-γ (pg/mL)	90.5 (15.3–613)	15.3 (9.8–42.6)	45.6 (9.7–121.1)	0.6171	0.0663
TNF-α (pg/mL)	0 (0–0)	1.9 (0–23.6)	0 (0–16.3)	0.6056	0.1097
IL-10 (pg/mL)	6.1 (2.6–10.1)	9.1 (2.6–24.1)	6.0 (2.8–40.8)	0.4237	0.5147
IL-18 (pg/mL)	483 (300–682)	579 (351–1680)	365 (237–610)	0.4235	0.0402

-At admission: no significant

-At the initiation of steroid use: serum **LDH**,  
**ALT**, **AST** and **IL-18** levels **significantly higher**  
in RMPP

The correlation between IL-18 and LDH: statistically significant  
→ **LDH** instead of IL-18 as a predictor of RMPP



**Fig. 1.** Correlation between serum values of IL-18 and LDH levels. A significant relation was found between serum values of IL-18 and LDH values.

$$(r^2 = 0.504, p = 0.0433)$$

- the serum LDH cut-off level / the initiation of steroid therapy: **412 IU/L** (ss 80%, sp 100% )

- serum LDH levels : useful marker for the evaluation of therapeutic efficacy in RMPP




Fig. 2. Serum values of lactate dehydrogenase in 5 pediatric patients with refractory *M. pneumoniae* pneumonia at five points before and after steroid treatment.



# RESPIRATORY CARE

## Lactate Dehydrogenase as a Biomarker for Prediction of Refractory *Mycoplasma pneumoniae* Pneumonia in Children

Aizhen Lu MD PhD, Chuankai Wang, Xiaobo Zhang MD PhD, Libo Wang MD, and Liling Qian MD PhD

### METHODS

- a prospective cohort study
- children with *MPP* admitted to the Children's Hospital of Fudan University
- September 2012 to August 2013
- n= **653**, 2 groups:RMPP group( 300) and GMPP group (353)

# Results

## LACTATE DEHYDROGENASE AS A BIOMARKER FOR *M. PNEUMONIAE* PNEUMONIA

Table 1. Comparison of Laboratory Findings on Admission for the Refractory and Usual *M. pneumoniae* Pneumonia Groups

Laboratory Test	Refractory <i>M. pneumoniae</i> Pneumonia Group	Usual <i>M. pneumoniae</i> Pneumonia Group	<i>P</i>
Creatine kinase, IU/L	116 ± 1,266 (13–986, 74)	89 ± 70 (2–825, 72)	.85
Creatine kinase MB, IU/L	35.7 ± 35.7 (9–189, 24)	30.2 ± 21.0 (6–230, 25)	.40
LDH, IU/L	449 ± 258	304 ± 78.1	< .01
HBDH, IU/L	357 ± 233	249 ± 69.3	< .01
Alanine aminotransferase, IU/L	23.2 ± 42.8 (1–394, 11.5)	12.4 ± 18.2 (1–219, 8.5)	< .01
Aspartate aminotransferase, IU/L	30.1 ± 28.7 (1–242, 21)	21.9 ± 20.7 (2–249, 18)	< .01
White blood cells, × 10 <sup>9</sup> /μL	8.62 ± 3.81 (2.1–28.9, 7.85)	8.23 ± 3.99 (1.8–43.9, 7.86)	< .01
Neutrophils, %	61.9 ± 15.0 (12.9–90.7, 63.7)	51.7 ± 17.1 (1.1–85.8, 54.0)	< .01
Lymphocytes, %	28.8 ± 13.5 (3.6–75.7, 27.0)	39.3 ± 16.3 (3.40–91.2, 35.6)	< .01
Platelets, × 10 <sup>9</sup> /μL	315 ± 125 (88–936, 299)	320 ± 116 (24–710, 315)	.23
C-reactive protein, mg/L	31.4 ± 39.1 (7–161, 7)	15.5 ± 20.5 (7–161, 7)	< .01
ESR, mm/h	40.8 ± 23.4 (6–125, 36)	28.2 ± 20.0 (0–102, 21)	< .01

## LACTATE DEHYDROGENASE AS A BIOMARKER FOR *M. PNEUMONIAE* PNEUMONIA

Table 2. Logistic Regression Analysis of Associated Factors in Refractory *M. pneumoniae* Pneumonia

Relevant Factor	B	SE	Wald	P	Odds Ratio	95% CI for OR	
						Lower	Upper
Age	0.014	0.004	10.197	.001	1.01	1.00	1.02
LDH	0.009	0.001	33.821	< .001	1.01	1.00	1.01
ESR	0.020	0.007	8.081	.004	1.02	1.00	1.03

LDH = lactate dehydrogenase

ESR = erythrocyte sedimentation rate

- serum LDH (odds ratio of 1.01, 95% CI 1.00–1.01,  $P < 0.001$ )

→ significant risk factors for RMPP / on admission

-The optimal cutoff of **LDH** for predicting RMPP: **379 IU/L**

ss: 48%, sp 85.8%, ppv 74.2%, npv 65.9%

# The Clinical Characteristics and Predictors of Refractory *Mycoplasma pneumoniae* Pneumonia in Children

Yuanyuan Zhang, Yunlian Zhou, Shuxian Li, Dehua Yang, Xiling Wu, Zhimin Chen\*

Department of Pulmonology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China

PLOS ONE | DOI:10.1371/journal.pone.0156465 May 26, 2016

## **METHODS**

-Retrospective analysis

-admitted to Children's hospital, Zhejiang University School of Medicine - January 1, 2011 and December 31, 2014

→n= 634, divided into two groups: GMPP (489 patients) and RMPP (145 patients )

# RESULTS

**Table 2. Laboratory characteristic of GMPP and RMPP patients.**

Laboratory information	GMPP (n = 489)	RMPP (n = 145)	P-value
White blood cell ( $\times 10^9/L$ )	8.22 (6.27~10.56)	7.60 (5.71~9.90)	0.106
Neutrophil, %	56.7 (43.4~65.6)	73.1 (65.3~78.5)	0.000
C-reactive protein (CRP), mg/L	6 (1~14)	36 (13~90)	0.000
Lactatedehydrogenase (LDH), IU/L	366 (310~459)	537 (419~666)	0.000
Prealbumin (PAB), g/L	0.12 (0.10~0.16)	0.08 (0.06~0.11)	0.000
Total Immunoglobulin (Ig), g/L			
IgG	9.36 (7.24~11.20)	8.96 (7.56~11.32)	0.823
IgA	0.85 (0.51~1.31)	1.20 (0.77~1.54)	0.000
IgM	1.54 (1.11~2.18)	1.66 (1.16~2.43)	0.138
Subpopulations of T lymphocytes, %			
CD3 <sup>+</sup>	61.48 (54.52~69.69)	61.97 (55.68~71.64)	0.243
CD4 <sup>+</sup>	33.97 (28.26~39.29)	34.26 (27.12~39.99)	0.909
CD8 <sup>+</sup>	21.16 (16.43~25.34)	22.63 (17.40~27.99)	0.040
Cytokines, pg/ml			
Interleukin 2 (IL-2)	2.6 (1.7~3.7)	2.5 (1.8~3.5)	0.883
IL-4	2.8 (2.2~3.4)	2.9 (2.2~3.5)	0.929
IL-6	9.7 (4.7~24.9)	34.2 (14.3 ~87.3)	0.000
IL-10	4.2 (3.1~6.1)	6.7 (4.7~10.0)	0.000
Tumor necrosis factor alpha (TNF- $\alpha$ )	2.9 (2.0~4.1)	3.0 (1.9~4.7)	0.866
Interferon gamma (IFN- $\gamma$ )	7.9 (4.6 ~12.2)	16.3 (8.3~49.3)	0.000

**Table 5. Stepwise logistic regression analysis for the related factors predicting the RMPP.**

Variable	B	S.E.	Wald	P-value	OR	95%CI	
						Lower	Upper
C-reactive protein (CRP) $\geq$ 16.5mg/L	0.705	0.330	4.570	0.033	2.023	1.060	3.861
Lactatedehydrogenase (LDH) $\geq$ 417IU/L	0.782	0.319	5.998	0.014	2.185	1.169	4.084
Interleukin 6 (IL-6) $\geq$ 14.75pg/ml	0.839	0.333	6.341	0.012	2.314	1.204	4.446

doi:10.1371/journal.pone.0156465.t005

- the cut-off values for **LDH** in differentiating RMPP from GMPP :**417IU/L**
- the sensitivity and specificity : **79.7%** and **65.0%**

# SUMMARY

- Many study indicates that serum LDH was elevated in RMPP: serum LDH can be used as a **biomarker** for **predicting refractory RMPP** and determining candidates who may benefit from corticosteroid therapy during the early stages of hospitalization
- However, the present study is limited by the small sample sizes of the component studies.

**Thank you for  
your attention!**